<DOC>
	<DOCNO>NCT02880852</DOCNO>
	<brief_summary>In China , Belimumab ( GSK1550188 ) develop dose regimen once-monthly intravenous ( IV ) infusion treatment SLE . This open-label , single dose study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) belimumab Chinese SLE subject . A total approximately 20 subject enrol receive IV infusion 10 milligram per kilogram ( mg/kg ) GSK1550188 Day 0 treatment SLE . Subjects follow 84 day administration drug .</brief_summary>
	<brief_title>Belimumab Phase I Study Chinese Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Subjects give consent study participation sign inform consent form . Subjects least 18 year age inclusive screening visit . SLE Classification : Have clinical diagnosis SLE accord American College Rheumatology ( ACR ) classification criterion , 4 11 ACR criterion present , serially simultaneously interval observation . SLE Treatment : Be either SLE medication stable SLE treatment regimen medication ( alone combination ) period least 2 month prior Day 0 ; corticosteroid ( prednisone prednisone equivalent , 40 mg/day ) ; immunosuppressive immunomodulatory agent include methotrexate , azathioprine , leflunomide , mycophenolate ( include mycophenolate mofetil , mycophenolate mofetil hydrochloride , mycophenolate sodium ) , mizoribine , calcineurin inhibitor ( example [ e.g . ] , tacrolimus , cyclosporine ) , sirolimus , oral cyclophosphamide , 6mercaptopurine , thalidomide ; antimalarial ( e.g. , hydroxychloroquine , chloroquine , quinacrine ) nonsteroidal antiinflammatory drug ( NSAIDs ) . The subject positive test antinuclear antibody ( ANA ) antidouble strand deoxyribonucleic acid ( DNA ) serum antibody . Males female : A female subject eligible enter study : pregnant nursing ; nonchildbearing potential ( i.e. , woman hysterectomy , postmenopausal define 1 year without menses , ovary surgically remove current document tubal ligation ) ; childbearing potential ( i.e. , woman functional ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhoea [ even severe ] , woman perimenopausal begin menstruate . These woman must negative serum pregnancy test screening , agree one following : complete abstinence penilevaginal intercourse , female 's preferred usual lifestyle , 2 week prior administration 1st dose investigational product ( IP ) study complete ; consistent correct use one follow acceptable method birth control 1 month prior start IP 16 week last dose IP : intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 percent ( % ) per year ; oral contraceptive ; double barrier method vaginal spermicidal agent : condom occlusive cap ( cervical cap/vault diaphragm ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) ; implant etonogestrel levonorgestrel ; estrogenic vaginal ring ; injectable progesterone ; percutaneous contraceptive patch ; male partner sterile prior female subject 's entry study sole sexual partner female subject . Based single average correct QT ( QTc ) interval value triplicate ECGs obtain brief recording period : [ QTc correct Bazett 's ( QTcB ) QTc correct Fridericia 's ( QTcF ) formula ] &lt; 450 millisecond ( msec ) ; QTcB QTcF &lt; 480 msec subject bundle branch block . Bcell Therapy : Have receive treatment B cell target therapy ( e.g. , rituximab , antiCD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] , BLySreceptor fusion protein [ BR3 ] , Transmembrane activator calciummodulator cytophilin ligand interactor [ TACI ] Fc , belimumab ) time . The subject receive biologic investigational noninvestigational agent within 12 month prior Day 0 . Received IV immunoglobulin ( Ig ) , plasmapheresis , hemodialysis , intravenous cyclophosphamide , high dose prednisone equivalent ( &gt; 60 mg/day ) within 6 month prior Day 0 . The subject receive nonbiologic investigational agent within 2 month prior Day 0 . The subject currently participate another clinical study postmarketing study subject expose investigational agent . The subject severe lupus kidney disease ( define proteinuria &gt; 6 gram [ g ] /24 hour ) within 6 month prior Screening visit . History renal transplant . Active central nervous system ( CNS ) lupus [ include seizure , psychosis , organic brain syndrome , cerebrovascular accident ( CVA ) , motor neuropathy , vasculitis ] require medical intervention within 6 month prior Screening visit . Infections : Have require management acute chronic infection , follow : currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) ; hospitalization treatment infection within 2 month prior Day 0 ; use parenteral ( IV intramuscular [ IM ] ) antibiotic ( antibacterial , antiviral , antifungal , anti parasitic agent ) within 2 month prior Day 0 . The subject hypogammaglobulinemia immunoglobulin A ( IgA ) deficiency ( IgA level &lt; 10 mg/deciliter [ dL ] ) . Have history anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . Uncontrolled disease : History clinical evidence active significant acute chronic disease ( i.e. , cardiovascular , pulmonary , untreated hypertension , anemia , gastrointestinal , hepatic , renal , neurological , cancer , infectious disease ) , opinion investigator , could confound result study put subject undue risk . Have plan surgical procedure , history medical disease , laboratory abnormality , condition would make subject ( opinion Investigator ) unsuitable study . The subject abnormality 12lead ECG screen clinically significant opinion investigator . Have evidence current drug alcohol abuse dependence . AST ALT &gt; =2x upper limit normal ( ULN ) ; ALP bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Have historically positive human immunodeficiency virus ( HIV ) test test positive screening HIV . History positive test screen visit Hepatitis B surface antigen ( HBsAg ) , anti Hepatitis B core antibody ( HBcAb ) antihepatitis C virus antibody ( HCVAb ) . If antiHBcAb result positive , hepatitis B virus ( HBV ) ( DNA ) test perform . If HBVDNA result negative , patient eligible . Laboratory Abnormalities : Have Grade 3 great laboratory abnormality base protocol toxicity scale except follow allow : Stable Grade 3 prothrombin time ( PT ) secondary warfarin treatment . Stable Grade 3/4 proteinuria ( = &lt; 6 g/24 hour equivalent spot urine protein creatinine ratio allow ) . Stable Grade 3 hypoalbuminemia due lupus nephritis , relate liver disease malnutrition . Stable Grade 3 neutropenia stable Grade 3 white blood cell count . Subjects evidence serious suicide risk include history suicidal behavior last 6 month , investigator 's opinion , pose significant suicide risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Chinese subject</keyword>
</DOC>